The quantitative 2-deoxy['4C]glucose autoradiographic method was used to map the distribution of alterations in local cerebral glucose utilization that accompanies clinically effective chronic L-dopa therapy of rhesus monkeys made parkinsonian by the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This pattern of changes was compared to the effects of a similar treatment regimen in normal monkeys. L-Dopa (100 mg with 10 mg carbidopa) was administered orally to normal and parkinsonian monkeys 3 times daily for 60-120 days prior to measurement of local cerebral glucose utilization. In parkinsonian monkeys treated with L-dopa, signs and symptoms of parkinsonism were controlled or suppressed, and widespread increases in glucose utilization were seen throughout the brain. Cerebral metabolic activity was increased both in areas rich in dopaminergic receptors, such as the caudate and putamen, and in nondopaminergic areas involved in motor functions. In many structures the rates of glucose utilization in L-dopatreated parkinsonian monkeys were increased to levels that far exceeded rates measured in normal monkeys. In sharp contrast, similar treatment with L-dopa in normal monkeys had little if any effect on local cerebral glucose utilization. L-Dopa, then, appears to have an action in animals with selective lesions of the substantia nigra pars compacta produced by MPTP that is distinctly different from its effects in the normal monkey.
L-Dopa (3,4-dihydroxy-L-phenylalanine) is the most effective and commonly prescribed drug for the treatment ofParkinson disease. Treatment with this dopamine precursor diminishes the severity of many signs and symptoms of Parkinson disease, including bradykinesia, tremor, and rigidity, and often restores relatively normal motor function (1) . Although its mechanisms of action are not fully understood, it is generally assumed that L-dopa enters the brain and is converted to dopamine, which then interacts with dopamine receptors to produce the therapeutic effects (2) . A further implicit assumption is that the site of this action is in the striatum, which in Parkinson disease is depleted of dopamine as a result of the degeneration of the dopaminergic nigrostriatal pathway.
In humans (3, 4) and nonhuman primates (5-8), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a typical parkinsonian syndrome, characterized by akinesia, rigidity, tremor, and flexed posture, that can be ameliorated by L-dopa treatment. MPTP administration causes almost complete and relatively selective destruction of the dopaminecontaining cells of the substantia nigra pars compacta and consequent depletion of dopamine and dopamine metabolites within the striatum (5) (6) (7) (8) . Because both the behavioral and the neuropathological characteristics of MPTP-induced parkinsonism in primates resemble human idiopathic Parkinson disease so closely, it appears that this syndrome provides an almost ideal animal model with which to study the effects of L-dopa treatment.
The autoradiographic 2-deoxy['4C]glucose (['4C ]dGlc) method (9) makes it possible to measure local rates of glucose utilization simultaneously throughout the entire central nervous system. Because energy metabolism is generally closely coupled to functional activity in the nervous system, the ['4C]dGlc method can be used to map local alterations in functional activity within the brain on the basis of changes in local rates of glucose utilization (10) . We have previously used the [14C]dGlc method to define the pattern of alterations in local cerebral energy metabolism associated with the parkinsonian syndrome induced by the administration of MPTP to rhesus monkeys (11) . Significant changes in glucose utilization were confined to the substantia nigra pars compacta, the subthalamic nucleus and the external segment of the globus pallidus within the basal ganglia, the frontal eye fields, and the mediodorsal nucleus of the thalamus. The purpose of the present study was to determine the nature and anatomic distribution of the effects of clinically effective chronic L-dopa therapy on local cerebral glucose utilization (LCGU) in MPTP-induced parkinsonian monkeys and to compare these effects with those of similar L-dopa administration in normal monkeys.
MATERIALS AND METHODS
Animals. Twelve adult rhesus monkeys (Macaca mulatta) of both sexes, weighing 5-8 kg, were studied. Six monkeys were made parkinsonian by administration of MPTP; six served as controls. All monkeys were housed in individual cages in heated and humidified quarters on a standard 12-hour light/dark cycle (light, 0700-1900). They were fed Purina Monkey Chow once daily and given water ad libitum.
Drug Administration. Crystalline MPTP (Aldrich; 97% pure) was dissolved in ethanol (8.7 mg/ml) and diluted with 9 volumes of water. Immediately before injection this solution was sterilized by filtration through a 22-aum Millipore filter. Each of six monkeys was given a total dosage of 1.7-3.6 mg of MPTP per kg of body weight, administered in equal Fig. 1 ).
DISCUSSION
The results show that the effects of chronic L-dopa therapy are distinctly different in MPTP-induced parkinsonian and normal monkeys. Whereas L-dopa therapy does not alter rates of LCGU in normal monkeys, it produces widespread increments in LCGU in brains of parkinsonian animals. These increases are not restricted to brain areas in which metabolism has been shown to be altered by MPTP-induced parkinsonism (11) . The pattern of changes in energy metabolism associated with parkinsonism itself is highly selective and includes only the external segment of the globus pallidus, the subthalamic nucleus, the frontal eye fields, and the mediodorsal nucleus of the thalamus (11) . Also, L-dopa treatment does not merely reverse the local cerebral metabolic effects of parkinsonism; for example, the increase in glucose utilization in the external segment of the globus pallidus in parkinsonism is not reduced to normal levels but rather is further augmented by L-dopa therapy. This observation, along with the widespread topographical distribution of metabolic changes that accompany chronic L-dopa therapy, suggests that the therapeutic actions of L-dopa do not (17) .
Measurement of LCGU cannot distinguish between direct and indirect actions of a drug; an entire pathway may be activated even though the direct action of the drug is exerted only at the origin of the pathway. The pattern of metabolic changes observed here reflects the metabolic events involved in the initiation of the central actions of L-dopa at dopaminergic receptors, as well as the secondary behavioral and functional consequences of L-dopa's actions, involving both dopaminergic and nondopaminergic pathways. The areas containing dopaminergic receptors in which metabolism was significantly activated by L-dopa treatment-i.e., the caudate, putamen, prefrontal cortex, and amygdala (18)-are innervated by dopamine-containing cells of the substantia nigra pars compacta rather than other dopaminergic cell groupings. Brain regions that receive dopaminergic inputs predominantly from the ventral tegmental area did not show L-dopa-induced increases in glucose utilization to the same degree as those areas that are innervated by the substantia nigra. Because the results obtained with the ['4C]dGlc method are not limited to the primary sites of action of the drug, it is not possible to conclude from these results whether the increases in glucose utilization seen in the subthalamic nucleus and the globus pallidus result from activation of dopaminergic receptors intrinsic to these areas (19) (20) (21) or are a result of dopaminergic activation of the striatum with consequent increased activity in pathways projecting from the striatum to the globus pallidus and subthalamic nucleus.
Glucose utilization was also increased in brain regions that are known to lack dopaminergic receptors but are known to be involved specifically in motor functions. The metabolic activation of these motor circuits, which include motor cortex, ventrolateral thalamus, cerebellum, and the internal segment of the globus pallidus, presumably was mediated indirectly by projections from the dopaminergically innervated striatum to the globus pallidus and in turn to the thalamus and cortex.
The rates of LCGU resulting from chronic L-dopa therapy of MPTP-induced parkinsonian monkeys were in many instances far greater than those seen in normal monkeys. Although the mechanisms by which L-dopa produces this metabolic "overshoot" in parkinsonian brain are not completely clear, they may be attributed to supersensitivity to dopamine. L-Dopa's therapeutic actions are believed to result from its conversion to dopamine and activation of dopaminergic receptors (2) . Further, the density of dopamine binding sites is increased in the striatum of animals with lesions of the substantia nigra pars compacta produced by 6-hydroxydopamine (22, 23) , MPTP administration (24), or idiopathic Parkinson disease (25, 26) . The action of L-dopa on supersensitive dopamine receptors in the striatum may lead to greatly increased striatal neuronal activity and, therefore, to hypermetabolic effects. Although denervation results in supersensitivity of dopamine receptors in the striatum, there is some evidence that long-term L-dopa administration can down-regulate dopamine receptors in animals and patients with lesions of the nigrostriatal system (27) (28) (29) (30) . Besides the increases in receptor density, however, other adaptive changes involved in the regulation of dopamine release and reuptake also occur following denervation and may contribute to the "overshoot" in cerebral metabolism associated with chronic L-dopa therapy of MPTP-induced parkinsonian monkeys.
There have been several reports of increased behavioral responsiveness to dopaminergic agonists following the chronic administration of L-dopa to normal intact rodents (31, 32) . In the present study, however, the initial administration of L-dopa to normal monkeys did not produce any significant alterations in behavior, and the response was unchanged with long-term L-dopa treatment. The lack of behavioral effects was consistent with the absence of LCGU changes following chronic L-dopa treatment of these monkeys. Whether the differences between these observations in the monkey from those in rodents result from species differences in the pharmacological response to chronic L-dopa or differences in dose or the time course of treatment is not clear.
